Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
RmeCx5KpgVzSbvMq
Listen
